| 臺大學術典藏 |
2019 |
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
|
Yang P.-W.;Liu Y.-C.;Chang Y.-H.;Lin C.-C.;Huang P.-M.;Hua K.-T.;Jang-Ming Lee;Hsieh M.-S.; Yang P.-W.; Liu Y.-C.; Chang Y.-H.; Lin C.-C.; Huang P.-M.; Hua K.-T.; JANG-MING LEE; Hsieh M.-S. |
| 臺大學術典藏 |
2019 |
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
|
Yang P.-W.;Liu Y.-C.;Chang Y.-H.;Lin C.-C.;Pei-Ming Huang;Hua K.-T.;Lee J.-M.;Hsieh M.-S.; Yang P.-W.; Liu Y.-C.; Chang Y.-H.; Lin C.-C.; PEI-MING HUANG; Hua K.-T.; Lee J.-M.; Hsieh M.-S. |
| 臺大學術典藏 |
2021-05-27T08:09:47Z |
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
|
Yang P.-W.;Liu Y.-C.;Chang Y.-H.;Lin C.-C.;Huang P.-M.;Kuo-Tai Hua;Lee J.-M.;Hsieh M.-S.; Yang P.-W.; Liu Y.-C.; Chang Y.-H.; Lin C.-C.; Huang P.-M.; KUO-TAI HUA; Lee J.-M.; Hsieh M.-S. |
| 臺大學術典藏 |
2021-08-22T00:00:08Z |
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Brose, Marcia S.; Robinson, Bruce; Sherman, Steven I.; Krajewska, Jolanta; Chia-Chi Lin; Vaisman, Fernanda; Hoff, Ana O.; Hitre, Erika; Bowles, Daniel W.; Hernando, Jorge; Faoro, Leonardo; Banerjee, Kamalika; Oliver, Jennifer W.; Keam, Bhumsuk; Capdevila, Jaume |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Brose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; Chia-Chi Lin; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J. |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
|
Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG; Rimassa L. |
| 臺大學術典藏 |
2021-08-31T06:29:27Z |
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
|
Abou-Alfa G.K.; Meyer T.; ANN-LII CHENG; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K. |
| 臺大學術典藏 |
2020-05-25T07:35:26Z |
Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial
|
Smith D.C; Smith M.R; Sweeney C; Elfiky A.A; Logothetis C; Corn P.G; Vogelzang N.J; Small E.J; Harzstark A.L; Gordon M.S; Vaishampayan U.N; Haas N.B; Spira A.I; Lara Jr. P.N; Chia-Chi Lin; Srinivas S; Sella A; Sch?ffski P; Scheffold C; Weitzman A.L; Hussain M. |
| 國立臺灣大學 |
2016 |
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)
|
Lu, Jeng-Wei; Wang, An-Ni; Liao, Heng-An; Chen, Chien-Yuan; Hou, Hsin-An; Hu, Chung-Yi; Tien, Hwei-Fan; Ou, Da-Liang; Lin, Liang-In; 林亮音; 陳建源; 田蕙芬; 胡忠怡; 侯信安 |
| 臺大學術典藏 |
2020-07-03T08:45:43Z |
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)
|
Lu J.-W;Wang A.-N;Liao H.-A;Chen C.-Y;Hou H.-A;Hu C.-Y;Tien H.-F;Da-Liang Ou;Lin L.-I.; Lu J.-W; Wang A.-N; Liao H.-A; Chen C.-Y; Hou H.-A; Hu C.-Y; Tien H.-F; DA-LIANG OU; Lin L.-I. |
